PDI Sticks to Contract Sales
While its competitors in the contract sales industry sell themselves as all-purpose marketing outsourcers, Professional Detailing Inc. is sticking to its core business of providing sales reps to pharmaceutical and biotech companies. Although PDI will eventually need to expand and diversify, most likely through acquisition, it should remain successful for some time as a pure play CSO.
You may also be interested in...
The drug industry has accepted the need to outsource R&D--now, with sales productivity down, and the rising cost and risk of owning too much commercial infrastructure, why not outsource more of the sales effort, too? Big and small pharmas resist the idea but will eventually have to accept it--junior partners in licensing deals are insisting on roles in selling their own products, and Big Pharma must investigate cost-saving solutions.
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.